What is CJC-1295 without DAC?

It is MOD-GRF 1-29, a 29-amino-acid GHRH analog with four amino acid changes that slow its breakdown. Without the DAC linker, it acts for a short time rather than for days.

Has CJC-1295 with ipamorelin been tested in humans?

Not as a combination. MOD-GRF 1-29 has very little human research of its own, ipamorelin has limited human data, and no published trial has studied them together.

Is CJC-1295 + Ipamorelin the same as HGH?

No. Neither peptide is growth hormone. They signal the pituitary to release its own, so the body's feedback still limits the response.

CJC-1295 + Ipamorelin: What the Stack Is, Research and Side Effects

What is CJC-1295 + Ipamorelin?

MOD-GRF 1-29, short for modified GRF 1-29, is the first 29 amino acids of human growth hormone-releasing hormone (GHRH) with four amino acid swaps that make it harder for enzymes to break down. It is designed to last longer than sermorelin, which uses the same sequence unmodified, but it is still short-acting.

Ipamorelin is a five-amino-acid peptide developed by researchers at Novo Nordisk in the 1990s. It acts on the ghrelin receptor, the same target as older growth hormone-releasing peptides like GHRP-6. In animal studies it released growth hormone without large rises in the stress hormones ACTH and cortisol. In humans, it reached trials for gut recovery after bowel surgery, where it did not show a clear benefit over placebo.

How does CJC-1295 + Ipamorelin work?

Growth hormone release is driven by two signals and held back by one. GHRH is the main driver, ghrelin is a second driver, and somatostatin is the brake. MOD-GRF 1-29 acts on the GHRH receptor. Ipamorelin acts on the ghrelin receptor and appears to counter somatostatin. The popular shorthand is that one peptide makes growth hormone and the other releases it. In reality both promote release, through separate routes.

Because MOD-GRF 1-29 is short-acting, the pairing aims for a strong but brief pulse rather than the steady rise seen with CJC-1295 with DAC. Human studies of other pairs, mainly GHRH with GHRP-6 or GHRP-2, found a larger growth hormone release together than with either alone. That synergy has not been measured for this exact pair.

Mixing it for research?

CJC-1295 (no DAC) + Ipamorelin reconstitution chart: how much bacteriostatic water to add to a 10 mg (5/5) vial and how many units each amount is, with Matthew’s step-by-step video.

See the mixing chart

Is CJC-1295 no DAC the same as CJC-1295?

No, and the names cause real confusion. The original CJC-1295 carries a Drug Affinity Complex (DAC), a linker that binds the peptide to albumin in the blood and stretches its half-life to about a week. MOD-GRF 1-29 has the same modified backbone without that linker, so it is cleared quickly and acts more like the body's own short bursts of GHRH. The labels are used loosely, and the published human studies of CJC-1295 used the DAC version.

What has research looked at?

This is a well-known stack with a thin evidence base. Its popularity rests on the mechanism and on user reports, not on clinical trials, so claims about muscle, fat loss, sleep or recovery from the pair are based on general growth hormone effects.

MOD-GRF 1-29: There is very little published human research on MOD-GRF 1-29 itself. What is known comes mostly from wider research on GHRH and analogs such as sermorelin and tesamorelin.
CJC-1295 with DAC: Small 2006 studies in healthy adults found the DAC version raised growth hormone and IGF-1 for days. Those results do not directly apply to the short-acting version.
Ipamorelin: Animal studies found selective growth hormone release and, in rats, increases in body weight and bone mineral content. Human studies mainly measured hormone levels.
The combination: No published clinical trial has tested MOD-GRF 1-29 and ipamorelin together.

Side effects and cautions

Short-term reports for both peptides describe mostly mild effects, but there are no long-term safety studies of either part or of the combination. Since both raise growth hormone and IGF-1, the general cautions of the growth hormone axis apply, and pairing two secretagogues may make those effects more likely. Talk to a qualified clinician before making decisions about any growth hormone-related compound.

Injection-site reactions: Redness, itching, pain or swelling at the injection site are the most commonly reported effects.
Flushing and headache: Brief warmth or flushing of the face and headache are reported with GHRH analogs.
Hunger: Ipamorelin is often described as causing little hunger, but it acts on the ghrelin receptor, so increased appetite is possible.
Fluid and joints: Higher growth hormone can cause water retention, swelling, joint aches and tingling or numbness in the hands.
Blood sugar and cancer history: Higher growth hormone can reduce insulin sensitivity. Because IGF-1 promotes cell growth, these compounds are generally avoided by people with active cancer, and any past history of cancer calls for careful review.